An Interventional Study of Infigratinib in Children With Hypochondroplasia
Clinical trial NCT06873035 · ENROLLING_BY_INVITATION
Trial details
- NCT number
- NCT06873035
- Sponsor
- QED Therapeutics, a BridgeBio company
- Status
- ENROLLING_BY_INVITATION
- Phase
- Phase 2, Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2025-04-22
- Primary completion
- 2027-01-01
- Enrollment
- 24
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.